NCT04156243 - CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions

B Cell LymphomaB Cell Leukemia

Interventions

BIOLOGICAL

CD19 CARvac T cells

CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Trial Locations (2)

Unknown

RECRUITING

The General Hospital of Western Theater Command, Chengdu

RECRUITING

Peking University Shenzhen Hospital, Shenzhen